Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Erytech Pharma S.a. Stock

Price
Target price
-

-

-
-
-
-
 
WKN: A2H7KA / Name: Erytech Pharma S.a. / Stock / ? /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Erytech Pharma S.a. in the next few years
Wizard

Erytech Pharma S.a. Stock

For the coming years our community has positive and negative things to say abot the Erytech Pharma S.a. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
What does Erytech Pharma S.a. do?

Pros and Cons of Erytech Pharma S.a. in the next few years

Pros
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-13

Upon examining the financial statements of Erytech Pharma S.A., it is evident that the company is in a unique position within its industry. It appears that the business has not been generating any revenue, as seen in the income statements for 2020, 2021, and 2022. Despite this, the company has maintained a relatively stable amount of total assets and liabilities throughout the period. This initial evaluation suggests that Erytech Pharma S.A. is a high-risk investment, as it has not demonstrated an ability to generate revenue. Nevertheless, a comprehensive analysis of their financial statements reveals some of the company's strengths and weaknesses.

Stable Total Assets: Erytech Pharma S.A.'s total assets have remained stable over the years between 2020 and 2022, ranging from €45.8 to €80.4 million. This stability indicates that the company has maintained a stable financial foundation during these years.

Sufficient Cash Reserves: The company has reported a substantial amount of cash on its balance sheet, with €38.8 million as of December 31, 2022. This reserve of cash provides the company with the flexibility to invest in research and development, operations, and other strategic initiatives.

Show more
Register To Post